Skip to main content Accessibility help
×
  • Cited by 15
      • Edited by Bernard Lerer, Hadassah-Hebrew Medical Center, Jerusalem
      Show more authors
    • You may already have access via personal or institutional login
    • Select format
    • Publisher:
      Cambridge University Press
      Publication date:
      20 August 2009
      29 August 2002
      ISBN:
      9780511543944
      9780521806176
      9780521189613
      Dimensions:
      (247 x 174 mm)
      Weight & Pages:
      1.108kg, 456 Pages
      Dimensions:
      (244 x 170 mm)
      Weight & Pages:
      0.73kg, 460 Pages
    You may already have access via personal or institutional login
  • Selected: Digital
    Add to cart View cart Buy from Cambridge.org

    Book description

    Pharmacogenetics and pharmacogenomics are areas of significant importance at the interface of molecular genetics and psychopharmacology, with implications for drug development and clinical practice. This 2002 book provides a conceptual framework for understanding and studying the pharmacogenetics of psychotropic drugs, reviews advances in the field, and describes the established findings. Coverage extends to antipsychotics, antidepressants, mood stabilising, cognitive-enhancing and anxiolytic drugs. Chapters also examine the interface of pharmacogenetics with substance dependence and brain imaging, and consider its impact on the biotechnology and pharmaceutical industries. This book defines the young field of pharmacogenetics as it applies to psychotropic drugs, and is therefore of interest to all clinicians and researchers working in this field.

    Reviews

    Review of the hardback:‘… this is a well-written book on a subject which is often found complicated and difficult … the book will be informative for the reader who wants a general review of the field of psychopharmacogenetics, but will also be useful for the reader who wants updated information on a specific topic …’European Journal of Clinical Pharmacology

    Review of the hardback:'This book gives a comprehensive review of the current state of the art covering almost all aspects of psychiatric pharmacogenetics. It provides an excellent introduction to the newcomer in this field and at the same time it is a most valuable source of information also for the experts.'Acta Psychiatrica Scandinavica

    Review of the hardback:'Bernard Lerer is to be congratulated in bringing together a group of authors who have presented an excellent, yet concise, overview of the importance of pharmacogenetics in contemporary psychopharmacology. … this monograph is recommended to all those wishing to keep abreast of this important area of neuroscience.'Human Psychopharmacology

    Refine List

    Actions for selected content:

    Select all | Deselect all
    • View selected items
    • Export citations
    • Download PDF (zip)
    • Save to Kindle
    • Save to Dropbox
    • Save to Google Drive

    Save Search

    You can save your searches here and later view and run them again in "My saved searches".

    Please provide a title, maximum of 40 characters.
    ×

    Contents


    Page 2 of 2


    • 21 - High-throughput single nucleotide polymorphism genotyping
      pp 422-440
      • By Anne Shalom, The Life Sciences Institute, The Hebrew University of Jerusalem, Israel, Ariel Darvasil, The Life Sciences Institute, The Hebrew University of Jerusalem, Israel; IDgene Pharmaceuticals Ltd, Jerusalem, Israel
    • View abstract

      Summary

      Maximizing drug response while minimizing adverse effects for individuals through the study of gene variations is the goal of pharmacogenomics. The most common type of human genetic variation is the Single nucleotide polymorphism (SNP), a position at which two alternative bases occur at appreciable frequency (>1%) in the human population. There are three major phases to SNP pharmacogenomics: SNP discovery and mapping, SNP scoring, and SNP diagnostics. Among these, the scoring step holds the greatest potential for uncovering medically important information. This step necessitates applying high-throughput SNP genotyping methods in the context of well-designed clinical pharmacogenetics correlation studies. This chapter presents the basic principle of the methods employed for SNP allele discrimination and detection. Most methods currently adopted require a preliminary amplification, by the polymerase chain reaction (PCR), of a small DNA fragment around the SNP to be analyzed.

    Page 2 of 2


    Metrics

    Altmetric attention score

    Full text views

    Total number of HTML views: 0
    Total number of PDF views: 0 *
    Loading metrics...

    Book summary page views

    Total views: 0 *
    Loading metrics...

    * Views captured on Cambridge Core between #date#. This data will be updated every 24 hours.

    Usage data cannot currently be displayed.

    Accessibility standard: Unknown

    Why this information is here

    This section outlines the accessibility features of this content - including support for screen readers, full keyboard navigation and high-contrast display options. This may not be relevant for you.

    Accessibility Information

    Accessibility compliance for the PDF of this book is currently unknown and may be updated in the future.